
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson’s Disease
NEU-723 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor First-of-its-kind companion diagnostic paired with NEU-723 will enable selection of patients likely to respond to therapy SOUTH SAN FRANCISCO, Calif. – February 7, 2023 – Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]